These training materials focus on the administration of the injectable contraceptive DMPA-SC by facility- and community-based family planning providers, as well as client self-injection. To access the PowerPoint files to customize for your training program, please email FPoptions@path.org. Note that these materials are currently being updated and revised versions will be posted in mid-2025.

The working meeting on “The Future of DMPA-SC: Expanding access and options in 2019” was held in November 2018 as a pre-meeting before the International Conference on Family Planning (ICFP) in Kigali, Rwanda was intended to bring together colleagues and partners working to introduce and scale-up subcutaneous DMPA (DMPA-SC) in 14 countries to exchange challenges, successes, and lessons learned—and to plan together how they can continue to expand women’s access and options with DMPA-SC.

This Global Health eLearning Center course provides an overview of the basic information relevant to family planning (FP) programs and services, including rationale for voluntary FP, contraceptive method considerations, contraceptive options (including short-acting, long-acting, and permanent methods), and FP for clients with special needs. It also addresses quality of services and access to care, as well as contraceptive security. Finally, the course highlights key tools to facilitate service delivery, client counseling, and provider training.

This handbook outlines the nine basic components of a community-based family planning program that includes injectables within the method mix provided by community health workers (CHWs). It includes in-depth content based on 15 years of experience and a global body of research from ministries of health, community-based organizations, national and international nongovernmental organizations, and other institutions from more than a dozen countries.

The handbook provides program managers, policy makers, and those interested in expanding access to family planning with insight to prepare, initiate, and scale up the provision of injectable contraception by CHWs. The lessons included were gleaned from research studies, programmatic reports, international medical guidance, and subject matter experts. The appendices contain a collection of checklists, training materials, sample forms, and other resources that can help you introduce and scale up CHW provision of injectable contraceptives.

Pfizer Inc. announced that the company’s injectable contraceptive, Sayana®Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for administration by self-injection. This follows the recent approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of an update to the Sayana® Press label, adding the option for self-injection by women when considered appropriate by a healthcare professional (HCP).

This 16-page paper provides an overview of the debate about how developing country drug regulation agencies are funded and the extent to which they should build local capacity or rely on regulators in developed countries.